Cargando…

Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model

BACKGROUND: The endocannabinoids system (ECs) mediated mainly by CB1 and CB2 receptors plays an important role in non-alcoholic fatty liver disease by regulating lipid metabolism. This study is to further investigate the expression of CB1 and CB2 in the fat accumulation liver cells and to identify p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Dongmei, zhan, Xi, Yu, Xiaofeng, Jia, Minglei, Zhang, Ying, Yao, Jianfeng, Hu, Xiaona, Bao, Zhijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247673/ https://www.ncbi.nlm.nih.gov/pubmed/25406988 http://dx.doi.org/10.1186/1476-511X-13-173

Ejemplares similares

Circadian Clock Genes in the Metabolism of Non-alcoholic Fatty Liver Disease
por: Shi, Dongmei, et al.
Publicado: (2019)

Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
por: ter Horst, Kasper W., et al.
Publicado: (2017)

The Role of Dietary Sugars and De novo Lipogenesis in Non-Alcoholic Fatty Liver Disease
por: Moore, J. Bernadette, et al.
Publicado: (2014)

Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
por: Paglialunga, Sabina, et al.
Publicado: (2016)

Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units
por: Hu, Xiaona, et al.
Publicado: (2012)

Raphani Semen (Raphanus sativus L.) Ameliorates Alcoholic Fatty Liver Disease by Regulating De Novo Lipogenesis
por: Park, Woo Yong, et al.
Publicado: (2021)

Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms
por: Cui, Yizhe, et al.
Publicado: (2019)

Trimetazidine improves hepatic lipogenesis and steatosis in non-alcoholic fatty liver disease via AMPK-ChREBP pathway
por: Zhang, Ying, et al.
Publicado: (2020)

Swietenine Alleviates Nonalcoholic Fatty Liver Disease in Diabetic Mice via Lipogenesis Inhibition and Antioxidant Mechanisms
por: Mak, Kit-Kay, et al.
Publicado: (2023)

Hemistepsin A inhibits T0901317-induced lipogenesis in the liver
por: Kim, Jae Kwang, et al.
Publicado: (2021)

Hepatoprotective effect of botanical drug formula on high-fat diet-induced non-alcoholic fatty liver disease by inhibiting lipogenesis and promoting anti-oxidation
por: Ning, De-Shan, et al.
Publicado: (2022)

miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease
por: Long, Jun-Ke, et al.
Publicado: (2019)

Melatonin Improves Fatty Liver Syndrome by Inhibiting the Lipogenesis Pathway in Hamsters with High-Fat Diet-Induced Hyperlipidemia
por: Ou, Tzu-Hsuan, et al.
Publicado: (2019)

Cynanchum atratum Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model
por: Wang, Jing-Hua, et al.
Publicado: (2021)

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies
por: von Loeffelholz, Christian, et al.
Publicado: (2021)

Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice
por: Lee, Da Som, et al.
Publicado: (2023)

Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis
por: Liu, Yan, et al.
Publicado: (2018)

Fatty Liver Due to Increased de novo Lipogenesis: Alterations in the Hepatic Peroxisomal Proteome
por: Knebel, Birgit, et al.
Publicado: (2019)

Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation
por: Wu, You, et al.
Publicado: (2021)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
por: Ideta, Takayasu, et al.
Publicado: (2015)

RF32 | PSUN44 CARF Regulates Non-Alcoholic Fatty Liver Diseases (NAFLD) by Controlling ER Stress and Lipogenesis in Hepatic Cells.
por: Friedman, Theodore, et al.
Publicado: (2022)

Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
por: Zhong, Yujie, et al.
Publicado: (2022)

Granulocytic MDSC with Deficient CCR5 Alleviates Lipogenesis and Inflammation in Nonalcoholic Fatty Liver Disease
por: Liao, Tzu-Chieh, et al.
Publicado: (2022)

Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver
por: Fu, Xiaorong, et al.
Publicado: (2023)

Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice
por: Kong, Qin, et al.
Publicado: (2016)

Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
por: Beysen, Carine, et al.
Publicado: (2020)

NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
por: Feng, Shenghu, et al.
Publicado: (2017)

Herbal SGR Formula Prevents Acute Ethanol-Induced Liver Steatosis via Inhibition of Lipogenesis and Enhancement Fatty Acid Oxidation in Mice
por: Qiu, Ping, et al.
Publicado: (2015)

Rhododendron oldhamii leaf extract improves fatty liver syndrome by increasing lipid oxidation and decreasing the lipogenesis pathway in mice
por: Liu, Ya-Ling, et al.
Publicado: (2017)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Chen, Ting, et al.
Publicado: (2022)

Clitorin ameliorates western diet-induced hepatic steatosis by regulating lipogenesis and fatty acid oxidation in vivo and in vitro
por: Cominguez, Divina C., et al.
Publicado: (2022)

LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease
por: Liu, Jun, et al.
Publicado: (2019)

Increased Hepatic Lipogenesis Elevates Liver Cholesterol Content
por: Berger, Jean-Mathieu, et al.
Publicado: (2021)

Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis
por: Bielawiec, Patrycja, et al.
Publicado: (2023)

Selective inhibition of liver X receptor α-mediated lipogenesis in primary hepatocytes by licochalcone A
por: Oh, Gyun-Sik, et al.
Publicado: (2015)

Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival
por: Nelson, Marin E., et al.
Publicado: (2017)

Ethanol Extract of Liriope platyphylla Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake
por: Le, Trang Nu Huyen, et al.
Publicado: (2021)

Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study
por: Jacobs, Simone, et al.
Publicado: (2015)

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kanuri, Giridhar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cj260dl6um71oe60nc1bgss8sn